Stifel lowered the firm’s price target on Vor Bio to $12 from $15 and keeps a Buy rating on the shares. The firm’s reduction in its price target mostly reflects extended Treatment System commercialization timelines and revised financing assumptions, but Stifel notes that it anticipates a number of important data catalysts to materialize in the second half of 2024 for Vor.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VOR:
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
- VOR Upcoming Earnings Report: What to Expect?
- Vor Bio treatment of acute myeloid leukemia granted FDA orphan designation
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Vor Bio to Participate in Upcoming Investor Conferences
